Pre-Made Telitacicept Biosimilar, Fusion Protein targeting TNFSF13B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Telitacicept Biosimilar, Fusion Protein targeting TNFSF13B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tanfanercept (HBM9036) is a modified 19 kDa TNF receptor 1 fragment. It is used to relief the signs and symptoms of dry eye disease (DED) and with good eye permeability, stronTelitacicept is a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor fused to the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG). Telitacicept binds and neutralizes the activity of two cell-signalling molecules, B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby suppressing the development and survival of plasma cells and mature B cells. Telitacicept is used for the treatment of B cell-mediated autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and multiple sclerosis (MS).g TNF-¦Á neutralizing activity, high stability, and minor side effects.
| Products Name (INN Index) | Pre-Made Telitacicept Biosimilar, Fusion Protein targeting TNFSF13B fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNF |
|---|---|
| INN Name | telitacicept |
| Target | TNFSF13B |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – [TNFRSF13B (tumor necrosis factor receptor (TNFR) superfamily member 13B, TACI, transmembrane activator and CAML Interactor)]2 – IGHG1 Fc (Fragment constant) |
| VD LC | Fusion – [TNFRSF13B (tumor necrosis factor receptor (TNFR) superfamily member 13B, TACI, transmembrane activator and CAML Interactor)]2 – IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | RemeGen,?Ltd. (Shandong China) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TNFSF13B |
| Package |
